Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126668231 | 12666823 | 1 | I | 20160808 | 20160819 | 20160819 | EXP | US-BAUSCH-BL-2016-019709 | BAUSCH AND LOMB | IRAGAVARAPU C, GUPTA T, CHUGH S, ARONOW W, FRISHMAN W. TYPE B LACTIC ACIDOSIS ASSOCIATED WITH VENLAFAXINE OVERDOSE. AMERICAN JOURNAL OF THERAPEUTICS. 2016;23(4):E1082-E1084. | 55.00 | YR | M | Y | 0.00000 | 20160819 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126668231 | 12666823 | 1 | PS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | AROUND 80 EXTENDED-RELEASE CAPSULES OF VENLAFAXINE, THE TOTAL DOSE BEING APPROXIMATELY 6000 MG | U | 90071 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126668231 | 12666823 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126668231 | 12666823 | HO |
| 126668231 | 12666823 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126668231 | 12666823 | Intentional overdose | |
| 126668231 | 12666823 | Lactic acidosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |